OBJECTIVES: Hysterectomy is the most common major gynecologic procedure in the world. Minimally invasive surgery is preferred to laparotomy due to its well-known benefits including lower blood loss, fewer perioperative complications, shorter hospital stay, quicker recovery time, and better cosmetic results. In 2014, the FDA issued a warning against the use of laparoscopic power morcellation in the majority of women undergoing myomectomy and hysterectomy for the treatment of fibroids, citing the risk of dissemination of an occult malignancy. Since the FDA statement, many institutions have banned or restricted the use of power morcellators. This study evaluated patients undergoing hysterectomy between April 17, 2014 and April 17, 2016. We compared the rate of hysterectomy via laparotomy vs. minimally invasive surgery (laparoscopic or vaginal) one year before and two years after the FDA warning. MATERIALS AND METHODS: This is a retrospective time-series analysis on all the hysterectomies performed for benign indications at Southern California Kaiser Foundation Hospitals between April 17, 2014 and April 17, 2016. Rate of abdominal vs. minimally invasive hysterectomies, estimated blood loss, length of operation and hospital stay, major post-operative complications, and hospital readmission within 30 days of surgery were compared in the one year before and the second year after the FDA warning. Post-operative complications included infection (superficial and deep), deep vein thrombosis, pulmonary embolism, wound dehiscence, fistula formation, and other unspecified post-operative complications. Analysis was performed using student T-test, ANOVA, and chisquared test for categorical variables. RESULTS: There were 18,252 hysterectomies performed in the three year study period. Those with missing records, age <18, pregnancy, and malignancy were excluded leaving 12,565 cases. Compared to one year before, there was a 5.4% and 5% increase in the rate of hysterectomies performed via laparotomy in the first year and second year after the FDA warning respectively (p < 0.001). There was no increase in the estimated blood loss, operative time, length of hospital stay, rate of re-admission, and post-operative complications (except pulmonary embolism). Similar results were obtained when sub-analysis was performed for hysterectomies with fibroid uterus as an indication for surgery. CONCLUSION: There was an increase in the rate of laparotomy for hysterectomy after the FDA morcellation warning. Despite this relative increase, there is no significant increase in the rate of immediate (30 day) post-operative complications or length of operation or hospital stay. This study did not assess parameters such as length of recovery or pain after surgery.
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19 Randomized controlled trial of two voiding trials after midurethral sling with or without colporrhaphy 
MATERIALS AND METHODS:
After enrollment, patients scheduled for outpatient MUS AE colporrhaphy were randomized to FOS or SVT. Patients were withdrawn if admitted or sustained cystotomy. Primary outcome was number of UPOV for voiding dysfunction or UTI. Voiding dysfunction is defined as urinary retention or postvoid residual (PVR) >200 cc. Secondary outcomes were catheterization after failed voiding trial (VT) & symptom assessment via the UDI-6 & AUA-SS. Retrograde-fill VT was performed in PACU at 1-hr (FOS) and within 2-3 hr (SVT). Force of urinary stream was recorded using a 100-point VAS, but used for research only in the SVT group. SVT subjects with a voided volume !2/3 instilled volume were discharged without a catheter. FOS subjects were discharged without a catheter if VAS was !50%; if <50% and PVR 499 cc, subjects were discharged with no catheter. Demographics, preoperative urodynamics, total recovery time, intraoperative and voiding trial data were collected. Follow-up time was 6-weeks. The criterion for noninferiority was an upper limit of <10% for the 90% CI. Analyses were performed using SAS version 9.4 (SAS Institute. Cary, NC). RESULTS: 102 subjects were included in the final analysis (49 FOS, 53 SVT). Demographics, prolapse stage, MUS type and concomitant surgery were similar in both groups. Immediate postoperative catheterization rates for FOS & SVT arms were 8.2% (n ¼ 4) and 9.4% (n ¼ 5) respectively (p ¼ 1.0000). PACU time was significantly less in the FOS group (2.1 h) compared to the SVT group (3.2 h) 
